Skip to main content

Table 4 Association between waiting time and the change in SF-12v2 physical component scale from baseline to the 6-month follow-up, for the overall sample and by main rheumatic condition

From: The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions

 

PCS at baseline, Mean (SD)

PCS at 6 months, Mean (SD)

GEE models

Unadj.

p value a

Unadj. change from baseline to 6 months, EMM (95% CI)

Adj.

p value a,b

Adj. change from baseline to 6 months, EMM b (95% CI)

Overall sample (n)

3210

1940

< 0.001

 

< 0.001

 

 Total

23.5 (9.7)

26.1 (11.2)

    

 < 2 months

24.3 (10.1)

28.2 (12.3)

 

3.8 [2.7, 4.9]

 

3.9 [2.7, 5.1]

 2–6 months

23.2 (9.8)

25.1 (10.6)

 

1.6 [0.7, 2.4]

 

1.6 [0.6, 2.5]

 > 6 months

23.0 (9.4)

25.3 (10.6)

 

1.9 [1.2, 2.6]

 

2.0 [1.2, 2.8]

Osteoarthritis (n)

665

395

0.009

 

0.057

 

 Total

24.7 (9.7)

27.5 (11.2)

    

 < 2 months

24.1 (9.8)

28.4 (11.4)

 

4.7 [2.1, 7.3]

 

4.3 [1.6, 7.0]

 2–6 months

24.6 (10.2)

27.0 (11.5)

 

1.7 [−0.4, 3.8]

 

1.8 [−0.6, 4.2]

 > 6 months

25.3 (9.2)

27.2 (10.7)

 

1.7 [0.02, 3.34]

 

1.9 [0.1, 3.8]

Fibromyalgia (n)

670

358

0.049

 

0.038

 

 Total

22.7 (9.6)

25.0 (11.0)

    

 < 2 months

22.7 (8.8)

26.8 (11.7)

 

4.4 [1.6, 7.2]

 

4.7 [1.6, 7.8]

 2–6 months

23.8 (10.1)

26.2 (11.3)

 

2.7 [0.8, 4.5]

 

2.3 [0.4, 4.3]

 > 6 months

21.6 (9.5)

22.9 (9.9)

 

1.6 [0.1, 3.1]

 

1.5 [−0.1, 3.1]

  1. PCS SF-12v2 Physical component scale, SD standard deviation, GEE generalized estimating equations, EMM estimated marginal means, 95% CI 95% confidence interval
  2. a Time X group effect p value
  3. b Adjusted for age, sex, pain duration, number of comorbidities and income